KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$100.56
+3.63%Oct 7, 2026, 11:00 UTC
Kodiak Sciences Inc. announced that it will present clinical data from all three late-stage programs at AAO 2026, including Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted, Phase 3 GLOW2 data for Zenkuda, and Phase 1b APEX data for KSI-101.
Source:Sep 28, 2026, 15:17 UTC
Regeneron Pharmaceuticals stock traded lower on Monday, likely in reaction to positive Phase 3 DAYBREAK trial data from Kodiak Sciences for wet age-related macular degeneration.
Source:Sep 28, 2026, 13:43 UTC
Kodiak Sciences announced that its eye disease drug met its clinical trial goals, sending the company's shares up 123%.
Sep 28, 2026, 13:32 UTC
Kodiak Sciences shares surged 104%, marking their largest single-day gain since December 2019.
Source:Sep 25, 2026, 22:01 UTC
Kodiak Sciences announced it will report topline results from the DAYBREAK Phase 3 study of Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in wet age-related macular degeneration on September 28, 2026.
Source:Aug 13, 2026, 00:00 UTC
Kodiak Sciences Inc. reported a net loss of $65.6 million, or $1.05 per diluted share, for Q2 2026, compared to a net loss of $54.3 million, or $1.03 per diluted share, in Q2 2025.
Source:Aug 11, 2026, 16:16 UTC
Kodiak Sciences initiated a global phase III clinical trial of KSI-501 for diabetic macular edema, evaluating a dual IL-6 and VEGF inhibitor approach.
Source:Jun 16, 2026, 16:09 UTC
Kodiak Sciences reported positive Phase 3 results for Zenkuda in diabetic retinopathy from the GLOW2 trial.
Source: